MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$12,268K
EPS
-$0.09
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
0
422
82*
159
Cost of sales
0
11
23*
64
Gross profit
0
411
59*
95
Research and development costs
9,148
9,122
6,121*
20,544
General and administrative expenses
4,717
7,026
4,959*
5,795
Restructuring charges
0
-
1,324*
0
Operating loss
-13,865
-15,737
-12,345*
-26,244
Foreign currency gain/(loss), net
151
-482
-14,269*
1,934
Other income, net
669
571
1,170*
770
Benefit from r&d credit
778
691
-286*
2,583
Loss before income tax expense
-12,267
-14,957
-25,730*
-20,957
Income tax expense
1
0
8*
1
Net loss
-12,268
-14,957
-25,738
-20,958
Basic EPS
-0.09
-0.11
-0.182
-0.15
Diluted EPS
-0.09
-0.11
-0.182
-0.15
Basic Average Shares
141,709,762
141,702,578
141,687,556
141,701,848
Diluted Average Shares
141,709,762
141,702,578
141,687,556
141,701,848
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$12,268K
Loss before income
tax expense
-$12,267K
Income tax expense
$1K
Benefit from r&d credit
$778K
Other income, net
$669K
Foreign currency
gain/(loss), net
$151K
Operating loss
-$13,865K
Research and development
costs
$9,148K
General and
administrative expenses
$4,717K
Buy us a coffee
Silence Therapeutics plc (SLNCF)
Silence Therapeutics plc (SLNCF)